Oncologia
Estudo randomizado | Em pessoas vivendo com HIV, o tratamento de lesões anais pré-cancerosas reduz mais da metade do risco de câncer anal.
22 Jun, 2022 | 21:45hComunicado de imprensa: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half – National Institutes of Health
Estudo original: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
Randomized trial showed that treating anal high-grade squamous intraepithelial lesions (HSILs) led to a 57% reduction in progression to anal cancer as compared with active surveillance. https://t.co/iulcskP61C pic.twitter.com/Q6Oqty3hgW
— NEJM (@NEJM) June 15, 2022
Definição de consenso e recomendações de tratamento: câncer de bexiga sem invasão muscular de risco intermediário.
22 Jun, 2022 | 21:24hIntermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group – European Urology – Oncology (se o acesso a este link for pago, tente este)
Comentário do autor no Twitter
Intermediate-risk NMIBC: Updated Consensus Definition & Management Recs from IBCG (International Bladder Cancer Group)
Full text: https://t.co/QaqGqRN3AE @drtanws @garysteinbergmd @DrShariat @UrogerliMD @MRoupret @spsutkaMD @joanfundi @MarekBabjuk @SWilliams_MD #bladdercancer pic.twitter.com/XQ1sdhqXPZ— Ashish M. Kamat, MD, MBBS (@UroDocAsh) June 17, 2022
Estudo randomizado | Lisocabtagene maraleucel vs. cuidado padrão com quimioterapia de resgate seguida de transplante autólogo de células-tronco como segunda linha de tratamento em pacientes com linfoma B de células grandes recidivante ou refratário.
22 Jun, 2022 | 21:22hLisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Onconefrologia: atualização da nefrotoxicidade relacionada à medicação anticâncer.
22 Jun, 2022 | 21:20hOnconephrology: Update in Anticancer Drug-Related Nephrotoxicity – Nephron
Conteúdos relacionados:
Comentário da autora no Twitter
Just published! Our review about anticancer drugs related kidney injury with @PepaSolerR and @julianadraibe @SENefrologia @onconephsociety @onconefrologia @senjoven @ERAkidney @womeninnephro https://t.co/jFStKwym5z @KargerPublisher pic.twitter.com/zvbl7wxAbD
— Clara García Carro (@ClaraGCarro) June 20, 2022
Estudo randomizado | Vigilância ativa com enzalutamida em monoterapia vs. vigilância ativa isolada em pacientes com risco baixo ou intermediário de câncer de próstata localizado.
22 Jun, 2022 | 20:57hComentário convidado: To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence – JAMA Oncology (gratuito por tempo limitado)
Vídeo criticando o artigo: ENACT trial | A Study That Makes Pharma Rich and Patients’ Poor | I break it down – by Vinay Prasad
Comentários no Twitter
55% fatigue and 36% gynecomastia. In AS patients.
Why do we keep trying to escalate when the data CLEARLY say we should continue to de-escalate? https://t.co/LY1kD0jN65
— Chris Barbieri (@Chris_Barbieri1) June 17, 2022
The phase 2, open-label ENACT trial compares the efficacy & safety of enzalutamide monotherapy vs active surveillance in patients with low- or intermediate-risk localized #prostatecancer. https://t.co/q9FrL14em1 #PCSM #GUCSM
— JAMA Oncology (@JAMAOnc) June 16, 2022
Análises clínicas e imunológicas de estudo de fase II | Sotigalimabe e/ou nivolumabe com quimioterapia no câncer pancreático metastático.
22 Jun, 2022 | 20:43hComunicado de imprensa: Promising results for chemo-immunotherapy combination against pancreatic cancer, Penn study finds – University of Pennsylvania
Comentário no Twitter
At #ASCO22 Symposium on targeted therapy in GI cancer?
Check out the results & biomarker analysis of the phase 2 PRINCE trial on a CD40 agonist, nivolumab and chemotherapy in #PancreaticCancer, led by speaker @laceykitch @parkerici
Published today 👉 https://t.co/8aUXuvDHIC
— Nature Medicine (@NatureMedicine) June 3, 2022
Diretriz NCCN atualizada | Câncer de mama.
21 Jun, 2022 | 12:58hEstudo de braço único fase 2B | Terapia focal centrada em ultrassom e guiada por ressonância magnética para pacientes com câncer de próstata de risco intermediário.
21 Jun, 2022 | 12:35hMRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comunicado de imprensa: High-intensity focused ultrasound (HIFU) can control prostate cancer with fewer side effects – Memorial Sloan Kettering Cancer Center
Comentário no Twitter
In single-arm phase IIb trial of MRI-guided focused ultrasound therapy in 101 men with primary, group 2‒3 intermediate-risk untreated prostate adenocarcinomas, 88% had no evidence of group ≥2 prostate cancer in the treated area at 2 years: https://t.co/xLpqfFm8Ds #PCSM
— NatureRevClinOncol (@NatRevClinOncol) June 16, 2022